Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application
PLOS One · 2025
DOI: 10.1371/journal.pone.0333341 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift PLOS One, 2025. Verfasst von Julia E M Upton und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Allergy, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Primary Immunodeficiency Diseases, Class I Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pharming Healthcare, Inc..
Abstract (Originalsprache)
Background
Activated phosphoinositide 3-kinase delta syndrome (APDS) is an ultra-rare, underrecognized inborn error of immunity. This study aimed to identify outcomes important in evaluating APDS treatment effectiveness and percent change in specific outcomes indicating a clinically meaningful benefit.
Methods
In this e-Delphi panel study, 28 globally based APDS experts used a 5-point Likert scale (Strongly Disagree to Strongly Agree) to indicate level of agreement that an outcome was an important measure of APDS treatment effectiveness in adult and pediatric patients at 3 and 6 months after treatment initiation. A threshold of ≥75% responding with “Agree” or “Strongly Agree” was considered consensus. Percent meaningful improvement in 6 outcomes was assessed and applied to APDS trial data (NCT02435173).
Results
Twenty-four panelists participated; e-Delphi rounds 1–5 were completed by 23, 21, 18, 17, and 16 panelists, respectively. Outcomes with the highest degree of consensus included lymph node size/volume, clinician overall impression of disease activity, antibiotic use, patient/caregiver-reported social outcomes and patient quality of life, hospitalizations, thrombocytopenia, spleen volume, lymphopenia, and anemia. Panelists indicated within-patient clinically meaningful improvements in adult patients ranged from median values of 20%−25% in lymph nodes, naïve B-cell to total B-cell ratio, spleen volume, hemoglobin, platelets, and lymphocytes at 3 months, and 25%−30% at 6 months. Panelists indicated within-patient clinically meaningful improvements in pediatric patients ranged from median values of 20%−27.5% at 3 months and 22.5%−45% at 6 months in the same 6 outcomes. In an application of responder thresholds, treatment with leniolisib resulted in significant and meaningful improvements in disease hallmarks, including lymph node size, spleen volume, and naïve B-cell ratio.
Conclusion
This study provides expert consensus on outcomes important in assessing APDS treatment effectiveness and improvement thresholds in 6 treatment outcomes indicative of a clinically meaningful benefit. These outcomes may help optimize APDS treatment in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Immunology and Allergy, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Paediatrics, Temerty School of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Medical University of South Carolina, Charleston, South Carolina, United States of America.
- Newcastle University, Newcastle upon Tyne, United Kingdom.
- CEGIST, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.
- Decision Eyes Lda, Lisbon, Portugal.
ORCID-Profile: Julia E M Upton, Amanda Harrington
Förderung
- Pharming Healthcare, Inc.
Zitieren
APA
Upton, J. E. M., Williams, K. W., Cant, A., Santos, A., Bana E Costa, J., Bradt, J., Harrington, A., & Gwaltney, C. (2025). Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application. PLOS One. https://doi.org/10.1371/journal.pone.0333341
Vancouver
Upton JEM, Williams KW, Cant A, Santos A, Bana E Costa J, Bradt J, et al. Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application. PLOS One. 2025. doi:10.1371/journal.pone.0333341
BibTeX
@article{Upton2025,
author = {Upton, Julia E M and Williams, Kelli W and Cant, Andrew and Santos, Ana and Bana E Costa, João and Bradt, Jason and Harrington, Amanda and Gwaltney, Chad},
title = {Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0333341}
}
EUVIMED